Micro-costing for national-scale azithromycin mass drug administration to improve child survival in Niger
Bibliographic Data
As programs for azithromycin mass drug administration (AZ-MDA) to reduce child mortality have begun in some parts of West Africa, it is imperative to understand their financial costs. We combined a micro-costing framework and observations from an implementation-focused sub-study within the AVENIR trials in 80 communities in the Dosso region of Niger to estimate the national health sector financial costs of a scaled-up programmatic approach for azithromycin biannual distribution to children aged 1–59 months of age living in nonurban areas, using the door-to-door modality. Our outcomes of interest were the annual budget at the regional and national levels for Niger and the cost per dose delivered. We found that the annual national budget required for AZ-MDA achieving 90% average coverage would be $12.5 million (M) (95% Uncertainty Interval (UI) $12.2M, $13.0M) translating to $1.59 (95% UI $1.40, $2.30) per dose delivered. Across regions, cost per dose would vary from $1.17 (95% UI $1.03, $1.69) to $3.61 (95% UI $3.20, $5.16), with higher cost per dose expected for more sparsely populated regions. Training costs represented a large fraction (16.4%) of total costs, and integration of training with that for existing health interventions may provide opportunities for efficiency
Azithromycin · Baseline (sea) · Confidence interval · Cost–benefit analysis · Drug administration · Food and drug administration · Mass drug administration · Psychological intervention · Total cost · Global Maternal and Child Health · Health Systems, Economic Evaluations, Quality of Life · Pneumonia and Respiratory Infections
Global, regional, and national trends in under-5 mortality between 1990 and 2019 with scenario-based projections until 2030
Integration of azithromycin mass administration to 1–11-month-old children into an existing health platform to reduce child mortality
Comparison of door-to-door and fixed-point delivery of azithromycin distribution for child survival in Niger
Feasibility and acceptability of integrating mass distribution of azithromycin to children 1–11 months into a trachoma mass drug administration campaign to reduce child mortality in Côte d’Ivoire
Costs and cost-effectiveness of community health worker programs on reproductive, maternal, newborn and child health in low- and middle-income countries (2015–2024)
Age-based targeting of biannual azithromycin distribution for child survival in Niger
Cost and cost-effectiveness of nationwide school-based helminth control in Uganda
| Citation velocity | historical |
|---|---|
| Highly cited | No |